| 000 | 04801nam a22005295i 4500 | ||
|---|---|---|---|
| 001 | 59978 | ||
| 005 | 20200226102525.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 161017s2017 gw | s |||| 0|eng d | ||
| 020 |
_a9783319321103 _9978-3-319-32110-3 |
||
| 024 | 7 |
_a10.1007/978-3-319-32110-3 _2doi |
|
| 035 | _a(DE-He213)978-3-319-32110-3 | ||
| 050 | 4 | _aRC254-282 | |
| 072 | 7 |
_aMJCL _2bicssc |
|
| 072 | 7 |
_aMED062000 _2bisacsh |
|
| 082 | 0 | 4 |
_a616.994 _223 |
| 245 | 1 | 0 |
_aOvarian Cancers _h[electronic resource] : _bAdvances through International Research Cooperation (GINECO, ENGOT, GCIG) / _cedited by Eric Pujade-Lauraine, Isabelle Ray-Coquard, Fabrice Lécuru. |
| 264 | 1 |
_aCham : _bSpringer International Publishing : _bImprint: Springer, _c2017. |
|
| 300 |
_aX, 286 p. 12 illus., 9 illus. in color. _bonline resource. |
||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 347 |
_atext file _bPDF _2rda |
||
| 505 | 0 | _aOvarian cancer management -- Clinical research in Europe dedicated to ovarian cancers -- Oncogenetics -- Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality -- How to evaluate tumor burden before therapeutic decision -- Value of lymphadenectomy -- HYPEC: what is the evidence? -- Onco-fertility applied to ovarian cancers -- First-line systemic therapy (chemo/antiangiogenics) -- Elderly -- Treatment at relapse (surgery & systemic treatments) -- How to evaluate QoL -- The future in ovarian cancers & place of the new immunotherapies in ovarian cancers -- Particular types of ovarian cancers -- High grade serous carcinoma & BRCA mutation anti-PARP -- Borderline and low grade carcinoma -- Clear Cell carcinoma -- Endometrioid carcinoma -- Mucinous carcinoma -- Carcinosarcoma -- Germ cell tumors -- Sex cord tumors -- Very rare ovarian malignant tumors including small cell carcinoma. Ovarian cancer management -- Clinical research in Europe dedicated to ovarian cancers -- Oncogenetics -- Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality -- How to evaluate tumor burden before therapeutic decision -- Value of lymphadenectomy -- HYPEC: what is the evidence? -- Onco-fertility applied to ovarian cancers -- First-line systemic therapy (chemo/antiangiogenics) -- Elderly -- Treatment at relapse (surgery & systemic treatments) -- How to evaluate QoL -- The future in ovarian cancers & place of the new immunotherapies in ovarian cancers -- Particular types of ovarian cancers -- High grade serous carcinoma & BRCA mutation anti-PARP -- Borderline and low grade carcinoma -- Clear Cell carcinoma -- Endometrioid carcinoma -- Mucinous carcinoma -- Carcinosarcoma -- Germ cell tumors -- Sex cord tumors -- Very rare ovarian malignant tumors including small cell carcinoma. | |
| 520 | _aThis book provides an overview of the latest developments in the concepts and management of ovarian cancer. The new data presented throughout opens the way to radically different therapeutic approaches. Surgery remains the core of ovarian cancer treatment, but its ultimate goal and the standard surgical procedure have evolved, giving rise to the question of how to label expert centers for debulking surgery. Neo-adjuvant chemotherapy is becoming more popular and is also a new field for testing novel drug combinations. Over recent years, ovarian cancer management has embraced molecular biology. It is now more correct to talk about cancers of the ovary rather than ovarian cancer, since it is not a unique disease but several entities with different molecular drivers. The significant advances in drugs targeting the microenvironment or the tumor cell DNA repair mechanisms are presented in detail together with exciting future perspectives. All these advances would not have been possible without collaborative groups such as the GINECO group in France and their integration in wider clinical research networks at the European (ENGOT) and international (GCIG) level. | ||
| 650 | 0 | _aMedicine. | |
| 650 | 0 | _aGynecology. | |
| 650 | 0 | _aOncology. | |
| 650 | 0 | _aPathology. | |
| 650 | 0 | _aReproductive medicine. | |
| 650 | 0 | _aSurgical oncology. | |
| 650 | 1 | 4 | _aMedicine & Public Health. |
| 650 | 2 | 4 | _aOncology. |
| 650 | 2 | 4 | _aGynecology. |
| 650 | 2 | 4 | _aSurgical oncology. |
| 650 | 2 | 4 | _aReproductive medicine. |
| 650 | 2 | 4 | _aPathology. |
| 700 | 1 |
_aPujade-Lauraine, Eric. _eeditor. |
|
| 700 | 1 |
_aRay-Coquard, Isabelle. _eeditor. |
|
| 700 | 1 |
_aLécuru, Fabrice. _eeditor. |
|
| 710 | 2 | _aSpringerLink (Online service) | |
| 773 | 0 | _tSpringer eBooks | |
| 776 | 0 | 8 |
_iPrinted edition: _z9783319321080 |
| 856 | 4 | 0 | _uhttp://dx.doi.org/10.1007/978-3-319-32110-3 |
| 912 | _aZDB-2-SME | ||
| 999 |
_c6232 _d6232 |
||